Table 7.
Clinicopathological patient factors predictive of those in receipt of adjuvant chemotherapy.
| Parameter | Univariable |
Multivariable |
||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P-value | OR | 95% CI | P-value | |
| Age < 75 | 5.319 | 2.024-13.979 | .001a | |||
| IDC subtype | 1.709 | 0.677-4.312 | .257 | |||
| Tumour size > 20 mm | 1.809 | 0.579-2.048 | .791 | |||
| cT2 | 1.401 | 0.752-2.609 | .289 | |||
| Grade 3 | 1.611 | 0.676-3.838 | .282 | |||
| LVI | 0.997 | 0.976-1.018 | .753 | |||
| PgR− | 1.455 | 0.657-3.223 | .355 | |||
| Ki67 > 14% | 0.481 | 0.051-4.562 | .524 | |||
| SLNB+ | 3.699 | 1.868-7.323 | <.001a | |||
| ODX score > 25 | 4.345 | 1.449-13.026 | .009a | 4.368 | 1.382-13.801 | .012* |
Abbreviations: CI, confidence interval; cT2, clinical tumour stage 2 disease; IDC, invasive ductal carcinoma; LVI, lymphovascular invasion; ODX, OncotypeDX Recurrence Score testing; OR, odds ratio; PgR−, progesterone receptor negativity; SLNB+, positive sentinel lymph node biopsy.
OR; odds ratio, 95% CI; 95% confidence interval, IDC; invasive ductal carcinoma, cT2; clinical tumour stage 2 disease, LVI; lymphovascular invasion, PgR-; progesterone receptor negativity,
SLNB+; positive sentinel lymph node biopsy, ODX testing.
*
denotes statistical significance.